Simoa Neurology Assays
Simoa assays can detect neurological biomarkers, such as Neurofilament Light (NfL),Tau, GFAP and several others associated with brain injury and disease. With Simoa, these informative markers can be detected at much earlier stages, in blood, serum or plasma, enabling better understanding of the long-term effects and disease pathology without invasive measures. Quanterix has a strategic focus in neurodegeneration, neuroinflammation, traumatic brain injuries (TBI) and multiple sclerosis (MS) and is working with a rapidly growing network of academic researchers and pharmaceutical and biotech partners to drive advancements in head health research.
Interested in learning more? Request more information and one of our team will be in touch shortly.